Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

被引：6

作者：

Mambet, Cristina ^{[1
,2
,3
]}

Babosova, Olga ^{[4
]}

Defour, Jean-Philippe ^{[2
,5
]}

Leroy, Emilie ^{[1
,2
]}

Necula, Laura ^{[3
]}

Stanca, Oana ^{[6
,7
]}

Tatic, Aurelia ^{[7
,8
]}

Berbec, Nicoleta ^{[6
,7
]}

Coriu, Daniel ^{[7
,8
]}

Belickova, Monika ^{[9
]}

Kralova, Barbora ^{[10
]}

Lanikova, Lucie ^{[4
]}

Vesela, Jitka ^{[9
]}

Pecquet, Christian ^{[1
,2
]}

Saussoy, Pascale ^{[5
]}

Havelange, Violaine ^{[11
]}

Diaconu, Carmen C. ^{[3
]}

Divoky, Vladimir ^{[10
]}

Constantinescu, Stefan N. ^{[1
,2
,3
]}

机构：

[1] Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium

[2] Catholic Univ Louvain, de Duve Inst, Brussels, Belgium

[3] Stefan S Nicolau Inst Virol, Mol Profiling Myeloproliferat Neoplasms & Acute L, Bucharest, Romania

[4] Acad Sci Czech Republ, Inst Mol Genet, Dept Cell & Dev Biol, Prague, Czech Republic

[5] Catholic Univ Louvain, Clin Univ St Luc, Dept Biol Clin, Brussels, Belgium

[6] Coltea Clin Hosp, Dept Hematol, Bucharest, Romania

[7] Carol Davila Univ Med & Pharm, Dept Radiol Oncol & Hematol, Bucharest, Romania

[8] Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania

[9] Inst Hematol & Blood Transfus, Prague, Czech Republic

[10] Palacky Univ, Fac Med & Dent, Dept Biol, Hnevotinska 3, CZ-77515 Olomouc, Czech Republic

[11] Clin Univ St Luc, Serv Hematol, Brussels, Belgium

来源：

BLOOD | 2018年 / 132卷 / 25期

关键词：

ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA;

D O I：

10.1182/blood-2018-04-843060

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2695 / 2699

页数：7

共 50 条

[41] Is the JAK2 V617F Mutation a Hallmark for Different Forms of Thrombosis?
Zerjavic, Katja
Zagradisnik, Boris
Herodez, Spela Stangler
Lokar, Lidija
Krasevac, Marjana Glaser
Vokac, Nadja Kokalj
ACTA HAEMATOLOGICA, 2010, 124 (01) : 49 - 56
[42] Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J.
Massie, C. E.
Baxter, E. J.
Nice, F. L.
Gundem, G.
Wedge, D. C.
Avezov, E.
Li, J.
Kollmann, K.
Kent, D. G.
Aziz, A.
Godfrey, A. L.
Hinton, J.
Martincorena, I.
Van Loo, P.
Jones, A. V.
Guglielmelli, P.
Tarpey, P.
Harding, H. P.
Fitzpatrick, J. D.
Goudie, C. T.
Ortmann, C. A.
Loughran, S. J.
Raine, K.
Jones, D. R.
Butler, A. P.
Teague, J. W.
O'Meara, S.
McLaren, S.
Bianchi, M.
Silber, Y.
Dimitropoulou, D.
Bloxham, D.
Mudie, L.
Maddison, M.
Robinson, B.
Keohane, C.
Maclean, C.
Hill, K.
Orchard, K.
Tauro, S.
Du, M-Q
Greaves, M.
Bowen, D.
Huntly, B. J. P.
Harrison, C. N.
Cross, N. C. P.
Ron, D.
Vannucchi, A. M.
Papaemmanuil, E.
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (25): : 2391 - 2405
[43] CALR, JAK2 Exon 14, and JAK2 Exon 12 mutations profiles in patients with Myeloproliferative Neoplasms
Yasin, Elrashed B.
Alkhatabi, Heba
Ahmedah, Hanadi Talal
Felimban, Raed
Tayeb, Hossam H.
Alalla, Zainab Jawdat
Abdulqayoom, Heyam Abdulsamad
Alserihi, Raed
BIOSCIENCE RESEARCH, 2021, 18 (02): : 1699 - 1707
[44] Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
Lee, A-Jin
Kim, Sang-Gyung
Nam, Jun Yeb
Yun, Jaehum
Ryoo, Hun-Mo
Bae, Sung Hwa
BLOOD RESEARCH, 2021, 56 (04) : 259 - 265
[45] JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms
Wang, J.
Xu, Z.
Liu, L.
Gale, R. P.
Cross, N. C. P.
Jones, A. V.
Qin, T.
Ai, X.
Xu, J.
Zhang, T.
Sun, X.
Li, Q.
Zhang, P.
Zhang, Y.
Xiao, Z.
LEUKEMIA, 2013, 27 (08) : 1763 - 1767
[46] Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases
Inmaculada Rapado
Enriqueta Albizua
Rosa Ayala
Jose Angel Hernández
Luis Garcia-Alonso
Silvia Grande
Miguel Gallardo
Florinda Gilsanz
Joaquin Martinez-Lopez
Annals of Hematology, 2008, 87 : 741 - 749
[47] The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective
Wadleigh M.
Gilliland D.G.
Current Hematologic Malignancy Reports, 2006, 1 (2) : 75 - 80
[48] Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes, Raoul
Mesa, Ruben A.
LEUKEMIA & LYMPHOMA, 2011, 52 (07) : 1178 - 1187
[49] MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms
Patnaik, M. M.
Lasho, T. L.
Finke, C. M.
Gangat, N.
Caramazza, D.
Siragusa, S.
Hanson, C. A.
Pardanani, A.
Tefferi, A.
LEUKEMIA, 2010, 24 (04) : 859 - 860
[50] Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy IS-5320
Arai, Kunihito
Sakaguchi, Masahiro
Yui, Shunsuke
Kitano, Tomoaki
Miyata, Miho
Yogosawa, Mayumi
Nakayama, Kazutaka
Tajika, Kenji
Usuki, Kensuke
Kuroda, Junya
Uoshima, Nobuhiko
Kobayashi, Yutaka
Uchiyama, Hitoji
Kubota, Yasushi
Kimura, Shinya
Mori, Shinichiro
Hirai, Mitsuharu
Wakita, Satoshi
Yamaguchi, Hiroki
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2022, 44 (06) : 1102 - 1110

← 1 2 3 4 5 →